Publication Highlights

Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562-6. PubMed PMID: 27432875; PubMed Central PMCID: PMC5034737.

Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH, Keynote. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. Journal of Clinical Oncology. 2017;35(19):2125-32. PubMed PMID: 28441111.

Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, Alyea EP, Carlton VE, Chen YB, Cutler CS, Ho VT, Koreth J, Kotwaliwale C, Nikiforow S, Ritz J, Rodig SJ, Soiffer RJ, Antin JH, Armand P. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. British Journal of Haematology. 2016;175(5):841-50. PubMed PMID: 27711974; PubMed Central PMCID: PMC5123935.

Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. Journal of Clinical Oncology. 2017;35(1):24-31. PubMed PMID: 28034071; PubMed Central PMCID: PMC5455688.

Iqbal J, Shen Y, Huang X, Liu Y, Wake L, Liu C, Deffenbacher K, Lachel CM, Wang C, Rohr J, Guo S, Smith LM, Wright G, Bhagavathi S, Dybkaer K, Fu K, Greiner TC, Vose JM, Jaffe E, Rimsza L, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Armitage JO, Weisenburger DD, Staudt LM, Gascoyne RD, McKeithan TW, Chan WC. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood. 2015;125(7):1137-45. PubMed PMID: 25498913; PubMed Central PMCID: PMC4326773.

Nikolaenko L, Chen R, Herrera AF. Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. Therapeutic Advances in Hematology. 2017;8(10):293-302. PubMed PMID: 29051800; PubMed Central PMCID: PMC5638176.

Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS, Qian J, Hailemichael Y, Nurieva R, Dwyer KC, Roth J, Yi Q, Overwijk WW, Kwak LW. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nature Medicine. 2014;20(6):676-81. PubMed PMID: 24859530; PubMed Central PMCID: PMC4048321.

Qin H, Wei G, Gwak D, Dong Z, Xiong A, Kwak LW. Targeting tumor-associated myeloid cells for cancer immunotherapy. Oncoimmunology. 2015;4(3):e983961. PubMed PMID: 25949898; PubMed Central PMCID: PMC4404802.

Qin H, Wei G, Sakamaki I, Dong Z, Cheng WA, Smith DL, Wen F, Sun H, Cha SC, Neelapu SS, Kwak LW. Novel BAFF receptor antibody to natively folded and glycosylated recombinant protein eliminates drug-resistant human B cell malignancies in vivo. Clinical Cancer Research. 2017; in press.